Biocon Limited

Biocon Limited

Biocon Limited announced that its partner, Duopharma Biotech, secured multiple insulin tenders from Malaysia's Ministry of Health, valued at over MYR 225 million. Biocon's Malaysian subsidiary will supply short-acting recombinant human insulin, insulin glargine, and insulin aspart under these contracts, which include a three-year human insulin agreement and two-year agreements for insulin glargine and aspart. This reinforces Biocon's commitment to diabetes care in Malaysia, ensuring continued access to high-quality, cost-effective insulin therapies and strengthening its market presence.

Biocon Limited

Biocon Limited has issued a communication to its shareholders detailing the deduction of Tax at Source (TDS) on the final dividend for the financial year 2025-26. The Board had recommended a final dividend of 10% (Re. 0.50 per equity share) on May 7, 2026, which is subject to shareholder approval at the AGM on August 6, 2026, with July 3, 2026, as the record date. The notice outlines the applicable TDS provisions, varying rates based on shareholder categories and residential status, and requests shareholders to update their PAN and other relevant details to ensure correct tax deduction or exemption.